Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

High Dose Chemotherapy and Autologous Transplant for Neuroblastoma

Not Applicable

Completed

Conditions: Neuroblastoma

Interventions: Drug: Carboplatin
Biological: Autologous stem cell infusion
Biological: Granulocyte colony stimulating factor
Radiation: Radiation therapy
Drug: Isotretinoin (13-cis-retinoic acid)
Drug: Melphalan
Drug: Etoposide

First Posted Date: 2012-02-06

Last Posted Date: 2024-02-26

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 13

Registration Number: NCT01526603

Locations: 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States

Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma

Phase 2

Active, not recruiting

Conditions: Lymphoma

Interventions: Drug: carmustine
Drug: cytarabine
Drug: etoposide
Drug: thiotepa
Procedure: stem cell transplant
Drug: G-CSF

First Posted Date: 2012-01-18

Last Posted Date: 2021-08-17

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 113

Registration Number: NCT01511562

Locations: 🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 123 locations

Auto Transplant for High Risk or Relapsed Solid or CNS Tumors

Not Applicable

Completed

Conditions: Ewing's Family Tumors
Renal Tumors
Hepatoblastoma
Rhabdomyosarcoma
Soft Tissue Sarcoma
Primary Malignant Brain Neoplasms
Retinoblastoma
Medulloblastoma
Supra-tentorial Primative Neuro-Ectodermal Tumor (PNET)
Atypical Teratoid/Rhabdoid Tumor (AT/RT)

Interventions: Drug: Ifosfamide
Drug: Etoposide
Drug: Mesna
Biological: G-CSF
Drug: Anti-seizure prophylaxis
Drug: Busulfan
Drug: Melphalan
Drug: Ursodiol
Drug: Paclitaxel
Drug: Thiotepa
Drug: Carboplatin
Biological: Autologous stem cell infusion
Procedure: Leukapheresis
Radiation: Radiation

First Posted Date: 2012-01-06

Last Posted Date: 2024-02-26

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 44

Registration Number: NCT01505569

Locations: 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States

Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match

Phase 2

Terminated

Conditions: Acute Myelogenous Leukemia
Chronic Myelogenous Leukemia
Aplastic Anemia
Acute Lymphocytic Leukemia
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Multiple Myeloma
Hodgkins Disease
Non-Hodgkins Lymphoma

Interventions: Drug: Busulfan
Drug: Clofarabine
Drug: Fludarabine
Drug: Melphalan
Drug: Carmustine
Drug: Etoposide
Drug: Cytarabine

First Posted Date: 2011-12-28

Last Posted Date: 2013-11-25

Lead Sponsor: Texas Oncology Cancer Center

Target Recruit Count: 1

Registration Number: NCT01500161

Locations: 🇺🇸
Texas Oncology, Amarillo, Texas, United States

Study of Etoposide in Treating Patients With Recurrent or Metastatic Breast Cancer

Phase 2

Conditions: Breast Cancer

Interventions: Drug: Etoposide

First Posted Date: 2011-12-15

Last Posted Date: 2013-03-15

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 100

Registration Number: NCT01492556

Locations: 🇨🇳
Beijing Hospital of the Ministry of Health, Beijing, Beijing, China
🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳
Peking University Cancer Hospital, Beijing, Beijing, China

and more 11 locations

Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients

Phase 2

Completed

Conditions: Diffuse Large B Cell Lymphoma

Interventions: Drug: Ofatumumab
Drug: Etoposide
Drug: Ifosfamid
Drug: Mesna
Drug: Cytarabine
Drug: Methotrexate
Drug: Leukovorin
Drug: Granulocyte-Colony Stimulating Factor

First Posted Date: 2011-11-29

Last Posted Date: 2021-12-27

Lead Sponsor: Polish Lymphoma Research Group

Target Recruit Count: 77

Registration Number: NCT01481272

Locations: 🇵🇱
Instytut Hematologii i Transfuzjologii, Warszawa, Mazowieckie, Poland
🇵🇱
Dolnośląskie Centrum Transplantacji Komórkowych, Wrocław, Dolnośląskie, Poland
🇵🇱
Uniwersyteckie Cenrum Medyczne, Gdańsk, Pomorskie, Poland

and more 5 locations

Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma

Phase 1

Active, not recruiting

Conditions: Recurrent Adult Hodgkin Lymphoma

Interventions: Biological: basiliximab
Drug: carmustine
Drug: etoposide
Drug: cytarabine
Drug: melphalan
Other: pharmacological study
Other: laboratory biomarker analysis
Procedure: autologous hematopoietic stem cell transplantation
Biological: yttrium Y 90-labeled basiliximab

First Posted Date: 2011-11-22

Last Posted Date: 2024-03-19

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 25

Registration Number: NCT01476839

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

Prospective Study on HIV-related Hodgkin Lymphoma

Phase 2

Conditions: HIV-associated Hodgkin Lymphoma

First Posted Date: 2011-11-09

Last Posted Date: 2011-11-09

Lead Sponsor: Harlachinger Krebshilfe e.V.

Target Recruit Count: 130

Registration Number: NCT01468740

Locations: 🇩🇪
Infektionsmedizinisches Zentrum Hamburg, Hamburg, Germany
🇩🇪
Vivantes Auguste Victoria Klinikum, Berlin, Germany
🇩🇪
Ärzteforum Seestrasse, Berlin, Germany

and more 5 locations

Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide

Phase 1

Completed

Conditions: Non-Hodgkin's Lymphoma

Interventions: Drug: Bendamustine
Drug: Ofatumumab
Drug: Carboplatin
Drug: Etoposide
Procedure: CT Scan
Procedure: PET Scan
Genetic: Stem Cell Transplant (STC)

First Posted Date: 2011-10-24

Last Posted Date: 2023-12-19

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 38

Registration Number: NCT01458366

Locations: 🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States

NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma

Phase 2

Completed

Conditions: Lymphoblastic Lymphoma

Interventions: Drug: Prednisone
Drug: Vincristine
Drug: Daunorubicin
Drug: PEG-asparaginase
Drug: Erwinia asparaginase
Drug: Doxorubicin
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Thioguanine
Drug: Clofarabine
Drug: Methotrexate
Drug: Mercaptopurine
Drug: Dexamethasone
Drug: Hydrocortisone
Drug: Etoposide

First Posted Date: 2011-10-13

Last Posted Date: 2022-06-28

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 23

Registration Number: NCT01451515

Locations: 🇺🇸
Rady Children's Hospital San Diego, San Diego, California, United States
🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy